Pharma marketing audit: published findings and scope
Prescription products, diagnostics, consumer health and devices have different demand paths and constraints. The combined model cannot establish segment specific conversion or commercial outcomes.
The 9 published Pharma case highlights sum to $576k in annual figures, with a lower median of $64k. Each case explains its own outcome; the sum does not establish realized cash recovery.
What the Pharma figures mean
9 published Pharma cases: $64,000 lower median annual highlight figure. The estimator uses a separate $64k model reference. Equal figures in some sectors do not make these the same statistic.
The population is the 74 published case studies, with one selected highlight figure per case. It is not a representative sample of all SMBs or a total of every finding in each audit. A lower median is the middle value after sorting, using the lower of the two middle values for an even count. Published annual figures include different outcome types; they are not all collected cash, profit or recurring savings. Case publication dates do not establish common observation, implementation or recovery periods; use each case for its supported timing and outcome.
Prescription products, diagnostics, consumer health and devices have different demand paths and constraints. The combined model cannot establish segment specific conversion or commercial outcomes.
Where Pharma budgets leak
The 9 published pharma audits split across four patterns, and the largest single finding is one of the oldest lines in many budgets: congress and KOL sponsorship with no attributable share of voice or prescribing outcome ($88k a year, found in 7 days). Rep detailing and samples aimed at prescribers whose behavior never moved make up the rest of that group.
Media timing and overlap add 4 cases. Flighting followed a fixed calendar rather than the weeks when the eligible population converted, and teams planning in isolation bought the same high intent visitor twice, whether unbranded against branded search or HCP against patient budgets. Unit economics holds 3 more: patient acquisition that cost more than reimbursement returned, a channel discount set below product margin, and subscriber acquisition that ignored churn driven by claims restrictions.
Prescription products, diagnostics, consumer health and devices convert differently, and compliance limits what can be tracked. The audits below work inside those limits: they design compliant attribution first, then test each line against an outcome it can actually move.
Four patterns across the 9 published Pharma cases. Each card names the cases it rests on; open one for its evidence. The five patterns behind them are defined in the margin leak guide.
Congress, KOL and detailing spend with no tracked return
Sponsorships renewed on tradition, and rep detailing and samples aimed at prescribers whose behavior never moves, run without a share of voice or prescribing outcome attached.
2 of the 9 published cases · $64k to $88k a yearMedia weighted outside the windows that convert
Flighting set by the calendar rather than by when the eligible population is in market spends heavily when and where patients do not convert.
2 of the 9 published cases · $58k to $60k a yearBudgets bidding against each other
Unbranded and branded search, or HCP and patient teams planning in isolation, can buy the same high intent visitor twice.
2 of the 9 published cases · $64k to $78k a yearAcquisition and discounts above what they return
Patient acquisition that costs more than reimbursement pays, channel discounts set below product margin, and subscriber acquisition that ignores regulatory churn each lose money on the sale they win.
3 of the 9 published cases · $44k to $71k a year- Subscription acquisition ignored regulatory driven churn, +$44k a year
- Retail vet channel discounts were set below margin, +$49k a year
- Patient acquisition spend ran above what reimbursement paid, −$71k a year
$88,000 a year, found in 7 days
Congress and KOL sponsorship showed no measurable return. Six figure congress and KOL spend had no attributable share of voice or prescribing outcome.
The 9 Pharma audits
What the audit checks for Pharma
- Congress and KOL spend against tracked engagement outcomes
- HCP digital channel return benchmarking
- Regional and clinic level targeting overlap
- Compliance safe attribution design
- Field and digital engagement cost per interaction
Running paid search or paid social? Each has its own self scored checklist: the Google Ads audit checklist and the Meta ads audit checklist.
“Short version, we were about to cut the wrong thing. Glad we got this done first.”
$88k annual budget redirection identified in 7 days
Congress spend with a tracked return: 8% → 88%
“Six figures a year in congresses and KOL sponsorships, renewed on habit. Leslie tried to connect it to share of voice, engagement or prescribing and found no instrumentation at all. The unmeasurable part now funds engagement we can track.”
Leslie MartinSenior Auditor · signed this audit off“Founder was on the kickoff call, the auditor who did the work ran the readout. Small thing but I've never had that with a consultancy before. You actually talk to the people who know the answers.”
$134k a year, read a year after a 6 day audit
Contribution margin on the two top campaigns: −7% → +9%
“Revenue grew and cash didn't. Victoria rebuilt margin per order after shipping, returns and payment fees, and our two biggest prospecting campaigns were losing money on every sale. We stopped scaling them.”
Victoria MillerLead auditor on this audit“The thing that won me over was a line in the report that basically said "we can't prove this one, so we're not counting it". Nobody does that. Made me trust everything else in there.”
$118k a year of wasted spend cut in 7 days
Rebates paid on volume never actually earned: 19% → 1%
“Rebate expense outran distributor volume and we could not see why. Cristian reconciled rebates paid against volume actually shipped and paid for, tier by tier: accruals had run off gross purchase orders. Quarterly true ups now catch it.”
Cristian BragauSenior Auditor · signed this audit off“I've paid for a few of these "audits" over the years and they usually end with a pitch. This one ended with a list of what to fix and which parts we could do ourselves. Some of it was not what I wanted to hear. All of it was right.”
$96k a year of wasted spend cut in 7 days
App installs that funded a real account: 24% → 63%
“Installs looked great and funded accounts stagnated. David followed sign ups through to funding, and the bonus was buying registrations from people who claimed it and never transacted. Incentives now pay on activation, not the download.”
David JacksonSenior Auditor · signed this audit off“Solid work. Lost a star only because the first week dragged, mostly getting them access on our end so partly our fault. After that it moved fast and the readout was really clear.”
$92k a year found in 7 days
Enterprise deal margin lost to quarter end: 5 pts lost → 0 pts lost
“Bookings hit target while margin slipped. Cristian split our discounting by timing and rep: concessions spiked in the last days of every quarter because buyers had learned to wait. Approval thresholds fixed it without losing deals.”
Cristian BragauSenior Auditor · signed this audit off$88k a year of wasted spend cut in 7 days
Paid social proven to lift store visits: ~1 in 3 → 9 in 10
“Our CFO doubted that online ads drove store visits. David's matched market geo lift test proved the doubt right: footfall barely changed where the ads were off. The budget moved to markets and channels that passed the test.”
David JacksonSenior Auditor · signed this audit off$74k a year of wasted spend cut in 7 days
Courier bonuses paid into already full zones: 22% → 3%
“Incentive spend rose while service levels stayed flat. Alex matched bonus payouts against real time courier availability by zone: in dense areas we paid couriers who would have worked anyway. Bonuses now fire only where coverage is short.”
Alex PopSenior Auditor · signed this audit off$63k a year found in 6 days
Active users actually being billed: 93% → 99%
“Expansion lagged what we saw inside accounts. Victoria reconciled active users against billed seats: many customers used more seats than they paid for. Automated true ups now capture it, and nobody pushed back.”
Victoria MillerSenior Auditor · signed this audit off$62k a year found in 6 days
Qualified inbound calls that became bookings: 2 in 3 → 9 in 10
“Marketing hit every target and revenue stalled. Leslie followed our qualified calls into intake and about a third were dropped at busy times or never followed up. Fixing staffing and call handling converted demand we had already paid for.”
Leslie MartinSenior Auditor · signed this audit offThe five leak patterns every Pharma audit tests
Every Pharma audit tests the same five patterns that drain SMB marketing margin. The 2026 benchmark shows how often each one turns up across industries.
- Non incremental paid
- Attribution inflation
- Mispriced offers
- Retention leaks
- Discount habits